Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New findings about protection against pneumococcal disease

31.03.2005


Findings hoped to spur the development of an improved vaccine



Since 2000, U.S. infants have been routinely immunized against pneumococcal (Streptococcus pneumoniae) infection. Now, Boston researchers have made a surprising discovery about natural immunity to pneumococcus. Two related studies, led by Dr. Richard Malley of the Children’s Hospital Boston Division of Infectious Diseases and Dr. Marc Lipsitch of the Harvard School of Public Health, suggest that natural protection from pneumococcal disease may derive from some previously unrecognized immune mechanism, which could possibly be exploited for a new vaccine. The latest study appears in the current (March 29) issue of the Proceedings of the National Academy of Sciences.

In the U.S., before the advent of the pneumococcal conjugate vaccine, known as Prevnar, S. pneumoniae caused more than 7 million ear infections each year, half a million episodes of bacterial pneumonia, and life-threatening cases of meningitis and bacteremia. Prevnar is made up of material from the outer capsule of each of the seven pneumococcal strains most common in the U.S. This material triggers recipients’ immune systems to produce so-called anticapsular antibodies specific to those strains. However, Prevnar doesn’t work against many pneumococcal strains in the developing world, where pneumococcus kills nearly 1 million children annually, and it is expensive and difficult to manufacture, leading to chronic shortages. Moreover, in several studies, use of pneumococcal conjugate vaccines caused non-vaccine strains to become more common, raising concerns that Prevnar could eventually become ineffective even in the U.S. Of 90 known pneumococcal strains, Prevnar only covers seven.


Lipsitch and Malley first conducted epidemiologic studies in unvaccinated toddlers in the U.S., Israel, and Finland. As they reported in January in the online journal PLoS Medicine, the incidence of invasive disease from almost all pneumococcal strains fell by nearly half between 1 and 2 years of age. Yet, anti-capsular antibody concentrations increased only slightly, suggesting that a mechanism other than antibody to the pathogen’s outer capsule may be conferring natural protection against pneumococcal disease.

What then might provide this protection? Looking at the first step of pneumococcal disease, colonization of the nose and throat, Malley and Lipsitch were able to elicit long-lasting immunity to pneumococcus in mice independently of any antibodies. In the current (March 29) Proceedings of the National Academy of Science, they report that when mice were exposed to live pneumococci, or to a whole-cell vaccine developed in Malley’s lab, they were highly immune to pneumococcal colonization -- even if they were genetically unable to make antibodies. Moreover, mice exposed to a single pneumococcal strain became immune not just to that strain, but to others. The immunity appeared to arise from an effect on the immune system’s CD4+ T-cells, since mice that lacked these cells did not develop immunity.

"Textbooks say that naturally-acquired protection against pneumococcal disease depends on the development of antibody against the capsule of the bacterium," says Malley, who is also an assistant professor in pediatrics at Harvard Medical School. "We were surprised to find that protection was independent of not only antibody to the capsule, but also antibody of any specificity."

Overall, their findings suggest that while antibodies are sufficient for protection against pneumococcal disease, they may not represent the natural mechanism of protection.

"An interesting observation is that HIV-infected children, whose CD4+ cells are depleted by the virus, are at about a 200-fold higher risk for pneumococcal disease," Malley adds. "Our experiments in mice may provide an explanation for that vulnerability."

The whole-cell vaccine developed by Malley’s lab could potentially protect against all pneumococcal strains, Malley says. The vaccine, made of killed pneumococcal cells, was shown to prevent colonization and invasive disease when given to animals in the form of nose drops. Malley believes the vaccine stimulates CD4+ T-cells to identify components of pneumococcus that are identical in every strain and to provide protection at the earliest stage of infection, when pneumococcus is colonizing the nasal passages.

The whole-cell vaccine, or a derivative of it, would be a boon for the developing world, because it is inexpensive, covers all pneumococcal strains, and does not require refrigeration. Malley and colleagues are now working to define precisely how the whole-cell vaccine works immunologically, and determine what parts of the killed bacterium provide the actual protection. The ultimate goal is to test the vaccine in adult volunteers, and eventually in children.

Susan Craig | EurekAlert!
Further information:
http://www.childrens.harvard.edu

More articles from Health and Medicine:

nachricht Why might reading make myopic?
18.07.2018 | Universitätsklinikum Tübingen

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

NYSCF researchers develop novel bioengineering technique for personalized bone grafts

18.07.2018 | Life Sciences

Machine-learning predicted a superhard and high-energy-density tungsten nitride

18.07.2018 | Materials Sciences

Why might reading make myopic?

18.07.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>